{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:25:41Z","timestamp":1791213941125,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T00:00:00Z","timestamp":1458172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1038\/leu.2016.66","type":"journal-article","created":{"date-parts":[[2016,3,17]],"date-time":"2016-03-17T05:55:55Z","timestamp":1458194155000},"page":"1502-1509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia"],"prefix":"10.1038","volume":"30","author":[{"given":"W","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-H","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E E","family":"Hjort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K M","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L C","family":"Platanias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,17]]},"reference":[{"key":"BFleu201666_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD . Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290\u2013293.","journal-title":"Nature"},{"key":"BFleu201666_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","volume":"29","author":"J Cortes","year":"2011","unstructured":"Cortes J, Hochhaus A, Hughes T, Kantarjian H . Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in CML. J Clin Oncol 2011; 29: 524\u2013531.","journal-title":"J Clin Oncol"},{"key":"BFleu201666_CR3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.critrevonc.2014.11.001","volume":"93","author":"K Yang","year":"2015","unstructured":"Yang K, Fu LW . Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review. Crit Rev Oncol Hematol 2015; 93: 277\u2013292.","journal-title":"Crit Rev Oncol Hematol"},{"key":"BFleu201666_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ajh.23902","volume":"90","author":"HP Erba","year":"2015","unstructured":"Erba HP . Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Am J Hematol 2015; 90: 242\u2013249.","journal-title":"Am J Hematol"},{"key":"BFleu201666_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.clml.2013.11.002","volume":"14","author":"A Lau","year":"2104","unstructured":"Lau A, Seiter K . Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib. Clin Lymphoma Myeloma Leuk 2104; 14: 186\u2013196.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu201666_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of IM in patients with CML who have maintained complete molecular remission for at least 2 years. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu201666_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1182\/blood-2012-07-441956","volume":"121","author":"M Horn","year":"2013","unstructured":"Horn M, Glauche I, M\u00fcller MC, Hehlmann R, Hochhaus A, Loeffler M et al. Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 2013; 121: 378\u2013384.","journal-title":"Blood"},{"key":"BFleu201666_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFleu201666_CR9","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Drucker","year":"2006","unstructured":"Drucker BJ, Guilhot F, O\u2019Brien SG, Kantarjian H, Hochhaus A, Gabrilove JL et al. 5 year follow up of patients receiving imatinib for CML. N Engl J Med 2006; 355: 2408\u20132417.","journal-title":"N Engl J Med"},{"key":"BFleu201666_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nature03669","volume":"435","author":"F Michor","year":"2005","unstructured":"Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL et al. Dynamics of CML. Nature 2005; 435: 1267\u20131270.","journal-title":"Nature"},{"key":"BFleu201666_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/nm1487","volume":"12","author":"I Roeder","year":"2005","unstructured":"Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loffler M . Dynamic modeling of imatinib-treated CML: functional insights & clinical implications. Nat Med 2005; 12: 1181\u20131184.","journal-title":"Nat Med"},{"key":"BFleu201666_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tips.2007.03.003","volume":"28","author":"F Michor","year":"2007","unstructured":"Michor F . Quantitative approaches to analyzing imatinib-treated CML. Trends Pharmacol Sci 2007; 28: 197\u2013199.","journal-title":"Trends Pharmacol Sci"},{"key":"BFleu201666_CR13","unstructured":"Oncomine, Research Addition, University of Michigan, Ann Arbor www.oncomine.org)."},{"key":"BFleu201666_CR14","doi-asserted-by":"publisher","first-page":"12766","DOI":"10.1074\/jbc.M112.429696","volume":"288","author":"W Huang","year":"2013","unstructured":"Huang W, Bei L, Eklund EA . Fas associated phosphatase 1 (Fap1) influences \u03b2catenin activity in myeloid progenitor cells expressing the Bcr-abl oncogene. J Biol Chem 2013; 288: 12766\u201312776.","journal-title":"J Biol Chem"},{"key":"BFleu201666_CR15","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1074\/jbc.M706710200","volume":"283","author":"W Huang","year":"2008","unstructured":"Huang W, Zhu C, Wang H, Horvath E, Eklund EA . The interferon consensus sequence binding protein (ICSBP\/IRF8) represses PTPN13 gene transcription in differentiating myeloid cells. J. Biol. Chem. 2008; 283: 7921\u20137935.","journal-title":"J. Biol. Chem."},{"key":"BFleu201666_CR16","doi-asserted-by":"publisher","first-page":"619","DOI":"10.3109\/10428194.2012.720979","volume":"54","author":"W Huang","year":"2012","unstructured":"Huang W, Bei L, Eklund EA . Fas-associated phosphatase 1 (Fap1) mediates Fas-resistance in myeloid progenitor cells expressing the Bcr-abl oncogene. Leuk Lymphoma 2012; 54: 619\u2013630.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201666_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/sj.leu.2404239","volume":"20","author":"L Ysebaert","year":"2006","unstructured":"Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB et al. Expression of Bcatenin by myeloid leukemia cells predicts clonogenic capacities and poor prognosis. Leukemia 2006; 20: 1211\u20131216.","journal-title":"Leukemia"},{"key":"BFleu201666_CR18","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/sj.onc.1208431","volume":"24","author":"M Simon","year":"1995","unstructured":"Simon M, Grandage VL, Linch DC, Khwaja A . Constitutive activation of the Wnt\/B catenin signaling pathway in myeloid leukemia. Oncogene 1995; 24: 2410\u20132420.","journal-title":"Oncogene"},{"key":"BFleu201666_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood.V91.1.22","volume":"91","author":"M Schmidt","year":"1998","unstructured":"Schmidt M, Nagel S, Proba J, Thiede C, Ritter M, Waring JF et al. Lack of interferon consensus sequence binding protein transcripts in human myeloid leukemias. Blood 1998; 91: 22\u201329.","journal-title":"Blood"},{"key":"BFleu201666_CR20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1128\/MCB.20.4.1149-1161.2000","volume":"20","author":"SX Hao","year":"2000","unstructured":"Hao SX, Ren R . Expression of ICSBP is down-regulated in bcr-abl-induced murine CML and forced co-expression of ICSBP inhibits bcr-abl-induced MPD. Mol Cell Biol 2000; 20: 1149\u20131161.","journal-title":"Mol Cell Biol"},{"key":"BFleu201666_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0092-8674(00)81348-3","volume":"87","author":"T Holtschke","year":"1996","unstructured":"Holtschke T, Lohler J, Kanno J, Kanno Y, Fehr T, Giese N et al. Immuno-deficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996; 87: 307\u2013317.","journal-title":"Cell"},{"key":"BFleu201666_CR22","first-page":"853","volume":"118","author":"I Konieczna","year":"2008","unstructured":"Konieczna I, Horvath E, Wang H, Lindsey S, Saberwal G, Bei L et al. Constitutive activation of SHP2 cooperates with ICSBP-deficiency to accelerate progression to acute myeloid leukemia. J Clin Invest 2008; 118: 853\u2013867.","journal-title":"J Clin Invest"},{"key":"BFleu201666_CR23","doi-asserted-by":"publisher","first-page":"24082","DOI":"10.1016\/S0021-9258(19)51050-X","volume":"269","author":"J Saras","year":"1994","unstructured":"Saras J, Claesson-Welsh L, Heldin CH, Gonex LJ . Cloning and characterization of PTPL1, a PTP with similarities to cytoskeletal-associated proteins. J Biol Chem 1994; 269: 24082\u201324089.","journal-title":"J Biol Chem"},{"key":"BFleu201666_CR24","doi-asserted-by":"publisher","first-page":"8539","DOI":"10.1074\/jbc.272.13.8539","volume":"272","author":"J Yanagisawa","year":"1997","unstructured":"Yanagisawa J, Takahashi M, Kanki H, Yano-Yanagisawa H, Tazunoki T, Sawa E et al. The molecular interaction of Fas and Fap1. J Biol Chem 1997; 272: 8539\u20138545.","journal-title":"J Biol Chem"},{"key":"BFleu201666_CR25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0022-2836(02)00544-2","volume":"320","author":"G Kozlov","year":"2002","unstructured":"Kozlov G, Banville D, Ghering K, Ekiel I . Solution structure of the PDZ2 domain from cytosolic human phosphatase hPTP1E complexed with a peptide reveals contribution of the B2-B3 loop to PDZ domain-ligand interactions. J Mol Biol 2002; 320: 813\u2013820.","journal-title":"J Mol Biol"},{"key":"BFleu201666_CR26","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/bi101131f","volume":"49","author":"J Zhang","year":"2010","unstructured":"Zhang J, Sapienza PJ, Ke H, Chang A, Hengel SR, Wang H et al. Crystallographic and nuclear magnetic resonance evaluation of the impact of peptide binding to the second PDZ domain of protein tyrosine phosphatase 1E. Biochemistry 2010; 49: 9280\u20139291.","journal-title":"Biochemistry"},{"key":"BFleu201666_CR27","doi-asserted-by":"publisher","first-page":"17967","DOI":"10.1073\/pnas.0808303105","volume":"105","author":"Y Minami","year":"2008","unstructured":"Minami Y, Stuart SA, Ikawa T, Jiang Y, Banno A, Hunton IC et al. BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci USA 2008; 105: 17967\u201317972.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201666_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/978-1-60761-058-8_15","volume":"602","author":"C Peng","year":"2010","unstructured":"Peng C, Li S . CML mouse model in translational research. Methods Mol Biol 2010; 602: 253\u2013266.","journal-title":"Methods Mol Biol"},{"key":"BFleu201666_CR29","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1128\/MCB.01595-09","volume":"30","author":"W Huang","year":"2010","unstructured":"Huang W, Zhou W, Saberwal G, Konieczna I, Horvath E, Katsoulidis E et al. The interferon consensus sequence binding protein (ICSBP) decreases Bcatenin-activity in myeloid cells by repressing GAS2 transcription. Mol Cell Biol 2010; 30: 4575\u20134594.","journal-title":"Mol Cell Biol"},{"key":"BFleu201666_CR30","doi-asserted-by":"publisher","first-page":"8110","DOI":"10.1074\/jbc.M111.294884","volume":"287","author":"W Huang","year":"2012","unstructured":"Huang W, Hu L, Bei L, Hjort E, Eklund EA . The leukemia-associated fusion-protein Tel-platelet derived growth factor receptor B (Tel-PdgfRB) inhibits transcriptional repression of the PTPN13 gene by the interferon consensus sequence binding protein (Icsbp). J Biol Chem 2012; 287: 8110\u20138125.","journal-title":"J Biol Chem"},{"key":"BFleu201666_CR31","doi-asserted-by":"publisher","first-page":"9344","DOI":"10.1074\/jbc.272.14.9344","volume":"272","author":"EA Eklund","year":"1997","unstructured":"Eklund EA, Kakar R . Identification of TF1phox, a DNA binding protein that increases expression of gp91phox in myeloid leukemia cells. J Biol Chem 1997; 272: 9344\u20139355.","journal-title":"J Biol Chem"},{"key":"BFleu201666_CR32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1046\/j.1365-2141.1998.01033.x","volume":"103","author":"BD Lichty","year":"1998","unstructured":"Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol 1998; 103: 711\u2013715.","journal-title":"Br J Haematol"},{"key":"BFleu201666_CR33","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1172\/JCI41649","volume":"120","author":"KJ Eash","year":"2010","unstructured":"Eash KJ, Greenbaum AM, Gopalan PK, Link DC . CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest 2010; 120: 2423\u20132431.","journal-title":"J Clin Invest"},{"key":"BFleu201666_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nprot.2011.305","volume":"6","author":"AM Rossi","year":"2011","unstructured":"Rossi AM, Taylor CW . Analysis of protein-ligand interactions by fluorescence polarization. Nat Protoc 2011; 6: 365\u2013387.","journal-title":"Nat Protoc"},{"key":"BFleu201666_CR35","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/pro.674","volume":"20","author":"CJ Layton","year":"2011","unstructured":"Layton CJ, Hellinga HW . Quantitation of protein-protein interactions by thermal stability shift analysis. Protein Sci 2011; 20: 1439\u20131450.","journal-title":"Protein Sci"},{"key":"BFleu201666_CR36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1177\/108705710100600609","volume":"6","author":"MW Pantoliano","year":"2001","unstructured":"Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J Biomol Screen 2001; 6: 429\u2013440.","journal-title":"J Biomol Screen"},{"key":"BFleu201666_CR37","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/0006-291X(92)90459-X","volume":"187","author":"E Gruszecka-Kowalik","year":"1992","unstructured":"Gruszecka-Kowalik E, Haugwitz RD, Zalkow LH . Quinobene, a new potent anti-HIV agent. Biochem Biophys Res Commun 1992; 187: 1409\u20131417.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu201666_CR38","first-page":"397","volume":"34","author":"J Bigelow","year":"1993","unstructured":"Bigelow J, Mathews L, McCormack J . Analytical studies and murine pharmacokinetics of quinobene. Proc Am Assoc Cancer Res Annu Meet 1993; 34: 397.","journal-title":"Proc Am Assoc Cancer Res Annu Meet"},{"key":"BFleu201666_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/978-1-4615-4811-9_52","volume":"457","author":"AG Turkina","year":"1999","unstructured":"Turkina AG, Logacheva NP, Stromskaya TP, Zabotina TN, Kuznetzov SV, Sachibzadaeva KK et al. Studies of some mechanisms of drug resistance in CML. Adv Exp Med Biol 1999; 457: 477\u2013488.","journal-title":"Adv Exp Med Biol"},{"key":"BFleu201666_CR40","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657\u2013667.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201666","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201666.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:42:30Z","timestamp":1781916150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,17]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["BFleu201666"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.66","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,17]]},"assertion":[{"value":"13 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}